Intravenous immunoglobulin (IVIg) is used in the therapy of various autoimmune and inflammatory diseases. Recent studies in experimental models propose that anti-inflammatory effects of IVIg are mainly mediated by a2,6-sialylated Fc fragments. These reports further suggest that a2,6-sialylated Fc fragments interact with DC-SIGN 1 cells to release IL-33 that subsequently expands IL-4-producing basophils. However, translational insights on these observations are lacking. Here we show that IVIg therapy in rheumatic patients leads to significant raise in plasma IL-33. However, IL-33 was not contributed by human DC-SIGN 1 dendritic cells and splenocytes. As IL-33 has been shown to expand basophils, we analyzed the proportion of circulating basophils in these patients following IVIg therapy. In contrast to mice data, IVIg therapy led to basophil expansion only in two patients who also showed increased plasma levels of IL-33. Importantly, the fold-changes in IL-33 and basophils were not correlated and we could hardly detect IL-4 in the plasma following IVIg therapy. Thus, our results indicate that IVIg-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. Hence, IL-33 and basophil-mediated anti-inflammatory mechanism proposed for IVIg might not be pertinent in humans.
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I ntravenous immunoglobulin (IVIg) is a therapeutic preparation of normal pooled immunoglobulin G (IgG) obtained from the plasma of several thousand healthy donors. High-dose IVIg (1-2 g/kg) is widely used in the treatment of various autoimmune and inflammatory diseases including Kawasaki disease, idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, autoimmune blistering diseases, inflammatory myopathies, graft versus host disease and others [1] [2] [3] [4] . The cellular and molecular mechanisms of action of IVIg in these diverse diseases remain incompletely understood. However, available evidence both from experimental and clinical studies provide an indicator that IVIg could benefit these diverse diseases via several mutually non-exclusive mechanisms 2, [5] [6] [7] [8] [9] [10] . These mechanisms include inhibition of activation and functions of innate immune cells such as dendritic cells (DCs), monocytes, macrophages and neutrophils; inhibition of pathogenic effector T cells such as Th1 and Th17 cells; expansion of regulatory T cells (Tregs); modulation of B cell responses; and inhibition of complement pathways. In addition, IVIg has been shown to inhibit inflammatory cytokines and to augment anti-inflammatory molecules such as IL-10 and IL-1 receptor antagonist [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . IgGs are glycoproteins and contain fragment antigen-binding (Fab) regions that recognize antigens, and fragment crystallizable (Fc) regions that exert effector functions upon binding to Fcc receptors. The Fc fragments are glycosylated at Asn297 and recent studies in animal models advocate that anti-inflammatory effects of IVIg are mediated by a small fraction of antibodies that contain terminal a2,6-sialylated glycans at Asn297. It was proposed that a2,6-sialylated Fc fragments interact with dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin-positive (DC-SIGN 1 ) innate cells to release IL-33, which subsequently expands IL-4-producing basophils 22 . However, translational insights on these observations are lacking. Therefore, we investigated whether high-dose IVIg therapy induces IL-33 production in autoimmune patients, which in turn would mediate basophil expansion and IL-4 responses.
Results
IVIg therapy induces IL-33 in autoimmune patients. Previous work on the role of IL-33 in IVIg-mediated anti-inflammatory effects was performed in K/BxN serum-induced murine arthritis model. It should be noted that IVIg is not recommended for rheumatoid arthritis due to its inefficacy to relieve inflammation 4 . Therefore, K/BxN serum-induced murine arthritis model might not provide factual image of the mechanisms of IVIg in autoimmune patients. Earlier studies have indicated that IVIg therapy benefits patients with inflammatory myopathies 1, 4 . Therefore, by using heparinized blood samples of these patients (cohort 1 patients), we first investigated the repercussion of IVIg therapy on the induction of IL-33. We found that, out of nine patients, six had minimal level of plasma IL-33 prior to IVIg therapy. The pre-IVIg plasma level of IL-33 was in the range of 150.75 6 79.52 pg/ml (n 5 9) (Fig. 1a) . Following IVIg therapy, with an exception of one patient, all remaining patients had significant raise in plasma IL-33 and was in the range of 492.23 6 130.30 pg/ml (n 5 9) (Fig. 1a) . However, the increase in IL-33 following IVIg therapy was heterogeneous and was varying from 1.2 to 911-fold.
To confirm these results, we analyzed the plasma samples from another cohort of patients with inflammatory myopathies (n 5 4) or anti-neutrophil cytoplasmic antibody-associated vasculitis (n 5 3) (cohort 2 patients). Importantly, these patients also showed significant increase in plasma IL-33 following IVIg therapy (Fig. 1b) thus confirming the results obtained with cohort 1 patients. The pre-IVIg plasma level of IL-33 was 80.43 6 24.93 pg/ml (n 5 7) that increased to 291.58 6 34.40 pg/ml following IVIg therapy. Together, these results indicate that irrespective of pathologies, IVIg therapy in patients leads to increased plasma level of IL-33.
IVIg-induced IL-33 is not associated with an expansion of basophils. Basophils play a crucial role in the induction of Th2 responses 23, 24 . Recent data from K/BxN serum-induced murine arthritis model suggest that IVIg-induced IL-33 promotes basophil expansion 22 . Therefore, we investigated changes in the circulating basophils following IVIg therapy in cohort 1 patients. Basophils were identified based on the expression of FceRI and CD203c (Fig. 2a ) 25 . In contrast to the results from murine model, we found that IVIg therapy leads to basophil expansion only in two patients who also showed increased plasma level of IL-33 (Fig. 2b) . In other patients, basophils were either declined or unaltered. The changes in the proportion of basophils in the circulation following IVIg therapy were not statistically significant. Importantly, the fold-changes in IL-33 and basophils were not correlated (Fig. 2c) . Also contrary to previous report 22 , we could hardly detect IL-4 in the plasma of patients following IVIg therapy. Thus, these results demonstrate that IVIg therapy in patients does not lead to an expansion of basophils. Of note, a recent data from murine models of collagen antibody-induced arthritis and K/BxN serum transfer arthritis also reveal that therapeutic effect of IVIg is independent of sialylation and basophils . By generating humanized DC-SIGN-transgenic mice, the authors found that these transgenic mice express DC-SIGN on DCs, macrophages and monocytes in the blood, bone marrow and spleen. Importantly, higher percentage of monocytes in these transgenic mice expressed DC-SIGN 22 .
We analyzed the expression of DC-SIGN in human myeloid cells. Contrary to humanized DC-SIGN-transgenic mice, circulating human monocytes did not express DC-SIGN whereas its expression on macrophages was restricted to M2 type macrophages wherein up to 28% cells were positive for DC-SIGN. We could observe high expression of DC-SIGN (<100%) only in monocyte-derived DCs (Mo-DCs) (Fig. 3a) . In the human spleen, up to 24% splenocytes were positive for DC-SIGN (Fig. 3b) .
Therefore, we explored if Mo-DCs secrete IL-33 upon IVIg treatment. In contrast to proposition by Ravetch and colleagues, we could detect secreted IL-33 from IVIg-exposed DC-SIGN 1 Mo-DCs neither under non-inflammatory nor under inflammatory conditions (Fig. 3c) . Similarly, despite the presence of DC-SIGN 1 cells in the spleen, human splenocytes did not produce detectable levels of IL-33 upon IVIg exposure both under inflammatory and noninflammatory conditions (Fig. 3c) .
Discussion
Our results demonstrate that IVIg therapy induces IL-33 in autoimmune patients thus confirming the previous observation made in mice. However, IL-33 was not contributed either by splenic DC-SIGN 1 cells or myeloid DCs. Also, the amount of IL-33 induced in the patients was not sufficient to expand basophils. It should be noted that the quantity of IL-33 protein induced in the mice following IVIg treatment was not presented in the previous report. In addition, significant amount of data on IVIg was indirect rather than direct demonstration of IVIg-mediated regulation of cytokine network 22 . Authors showed that IVIg induces about 12-fold increase in IL-33 mRNA level. However, the contribution of this increased IL-33 mRNA towards IL-33 protein is not clear. Considering five liters as total blood volume in adults, our results show that IVIg induces <2460 6 650 ng of IL-33 (based on the data from cohort 1 patients). However, to demonstrate the role of IL-33 in IVIg-mediated antiinflammatory effects, Anthony et al., injected 400 ng of IL-33 for four consecutive days 22 . As mouse weighing 25 g would have <1.5 ml of blood, based on the IL-33 data from patients, we could infer that the amount of exogenous IL-33 injected into the mice represents at least 540-times excess of IL-33 that otherwise induced by IVIg. This might explain why IVIg failed to induce expansion of basophils in the patients. Although in our study, patients' sample size was small, we included diseases such as inflammatory myopathies and vasculitis that were shown to benefit from IVIg therapy. Further investigations in a larger number of patients should confirm these observations. The role of Fc-sialylation, DC-SIGN and Fcc receptor IIB (FccRIIB) in the anti-inflammatory effects of IVIg has been debated recently by several groups 27 . Mice and humans show wide variations in the expression pattern of FccRs, and the phenotype and anatomical distribution of innate cells. Unlike mice, human innate cells express both activating FccRIIA and inhibitory FccRIIB. Therefore, the proposition that IVIg enhances FccRIIB on effector macrophages of mice without having corresponding data on FccRIIA might provide a biased picture on the mechanisms of IVIg. Gene array analysis could not confirm IVIg-mediated up-regulation of FccRIIB in the patients with Kawasaki disease 28 . In line with this report, another recent study failed to demonstrate enhanced expression of FccRIIB on monocytes following IVIg therapy in children with immune thrombocytopenia 29 . Also, FccR polymorphisms did not predict response to IVIg in myasthenia gravis 30 . Although DC-SIGN promoter 2336 A/G (rs4804803) polymorphism was associated with susceptibility of Kawasaki disease, this variant was found to be not associated with the occurrence of IVIg resistance 31 . Of note, treatment response in Kawasaki disease is apparently associated with sialylation levels of endogenous IgG but not therapeutic IVIg 32 . All these data thus questions the relevance of DC-SIGNFccRIIB pathway of anti-inflammatory mechanisms of IVIg in humans.
Several recent studies have challenged the concept of a2,6-sialylated Fc fragments-mediated anti-inflammatory mechanism of IVIg both in experimental models and in humans. IVIg could inhibit human Th17 cell differentiation and expansion independent of antigen presenting cells and hence independent of interaction of DC-SIGN and a2,6-sialylated Fc fragments [13] [14] [15] . Also, F(ab') 2 fragments of IVIg exerted similar effects thus pointing towards dispensability of a2,6-sialylated Fc fragments in mediating the suppression of Th17 cells. We have demonstrated that DC-SIGN and a2,6-sialylated Fc fragment interaction is dispensable for the anti-inflammatory activity of IVIg on human DCs 33 . F(ab') 2 fragments but not Fc fragments of IVIg were shown to mediate Treg expansion by inducing cyclooxygenase-2-mediated prostaglandin E2 secretion in human myeloid DCs and was dependent in part on DC-SIGN 19 . Similarly, sialylationenriched F(ab') 2 fragments could inhibit interferon-a production from toll-like receptor (TLR)7 and TLR9 stimulated human plasmacytoid DCs, although sialic acid itself was not required 34 . In the previous reports, Ravetch and colleagues enriched sialic acid-containing IgG-Fc by using sialic acid-specific lectin Sambucus nigra agglutinin-based affinity fractionation 22, [35] [36] [37] . However, by using same fractionation method, Guhr et al., showed that IVIg fractions depleted for the sialylated antibody fraction exert benefits in a murine model of passive-immune thrombocytopenia similar to that of intact IVIg. However, sialic acid-enriched IVIg fraction failed to enhance platelets count in this model 38 . Similar sialic-acid independent anti-inflammatory mechanisms were also reported in murine herpes simplex virus encephalitis model 39 . Further, Käsermann and colleagues showed that lectin fractionation of IVIg results in increased sialylation of Fab fragments but not Fc fragments. By using human whole blood stimulation assay either with lipopolysaccharide or phytohaemagglutinin, they further showed that anti-inflammatory effects of IVIg is associated with F(ab') 2 fraction of IVIg 40 . In animal models of immune thrombocytopenia and multiple sclerosis, the beneficial effects of IVIg were independent of Fc or F(ab') 2 -sialylation and FccRIIB [41] [42] [43] [44] . Based on these results, it was suggested that genetic background of the mice and dose of IVIg are the critical factors that determine the role of FccRIIB in IVIg-mediated beneficial effects. In line with these observations, two studies have failed to demonstrate the direct interaction between sialylated IgG Fc fragment and DC-SIGN 45, 46 . These data thus point out that a2,6-sialylated Fc fragment-DC-SIGN-FccRIIB mechanism merely represents one of the several anti-inflammatory mechanisms of IVIg that were reported. Therefore, this anti-inflammatory pathway of IVIg might be operational in certain pathologies and experimental models and might not be considered as a universal mechanism.
It was proposed that in humanized DC-SIGN-transgenic mice, DC-SIGN 1 innate cells such as monocytes, macrophages and DCs produce IL-33 upon interaction with a2,6-sialylated Fc fragments of IVIg 22 . Recent reports show that IL-33 is an important player for the promotion of Th2 responses and activated DCs are one of the sources of this cytokine 47, 48 . We found that unlike monocytes from huma- nized DC-SIGN-transgenic mice that were highly positive for DC-SIGN, human monocytes hardly express DC-SIGN. Further, human Mo-DCs despite expressing DC-SIGN, failed to produce IL-33 when exposed to IVIg either under non-inflammatory or inflammatory conditions. In wild type mice, it was suggested that a2,6-sialylated Fc fragments bind to SIGN-R1 expressed on splenic marginal zone macrophages 35 . Marginal zone macrophages are absent in human spleen and data from humans show that spleen is dispensable for the anti-inflammatory effects of IVIg. In line with this concept, by using a passive model of induced immune thrombocytopenia, it was shown that IVIg is fully functional in splenectomized mice although this report supported the sialic acid and SIGN-R1-dependent mechanisms of IVIg 49 . We found that despite the presence of DC-SIGN 1 innate cells in the human spleen, IVIg could not induce IL-33 from the splenocytes. All these data indicate that spleen and DC-SIGN 1 cells are dispensable for IVIg-mediated IL-33 induction in humans. Thus, the source of IL-33 in humans following IVIg therapy remains elusive. As IVIg is known to cause apoptosis of cells, we suggest that secondary necrosis of late stage apoptotic cells could release IL-33 [50] [51] [52] . This process might depend on the signals provided by anti-Fas IgG or anti-Siglec IgG in the IVIg preparations rather than the repercussion of interaction of a2,6-sialylated Fc fragments with DC-SIGN 53, 54 . In addition, IL-33 is also constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo 55 .
Methods
Patients. All experiments were performed in accordance with relevant guidelines and regulations. We obtained heparinized blood samples of nine patients (cohort 1 patients) with inflammatory myopathies (Table 1) . Patients were aged 49.1 6 15.2 years and include two men. Blood samples were obtained before and 2-3 days following initiation of IVIg therapy (CLAIRYGH, Laboratoire Français du Fractionnement et des Biotechnologies, France). Informed consent was obtained from all the patients. The study was approved by CPP-Ile-de-France VI, Groupe Hospitalier Pitié-Salpêtrière, Paris. In addition, we also analyzed plasma samples of seven rheumatic patients (cohort 2 patients) before and 2-3 days post-IVIg therapy (TEGELINEH, Laboratoire Français du Fractionnement et des Biotechnologies). The patients were aged 47 6 5.8 years (four men) and include inflammatory myopathies and anti-neutrophil cytoplasmic antibody-associated vasculitis ( Table 1) .
Analysis of basophils.
Red blood cells (RBCs) from heparinized blood samples of cohort 1 patients were depleted by using HetaSepTM (Stemcell Technologies Sarl, France) and nucleated cell suspension was obtained. Basophils were analyzed in RBCdepleted cell suspension by flow cytometry (LSR II, BD Biosciences, France) using fluorochrome-conjugated monoclonal antibodies to FceRI (Miltenyi Biotec, France) and CD203c (eBioscience, France). Data were analyzed by FACSDiva TM software (BD Biosciences).
Generation of monocyte-derived DCs. Buffy coats from the healthy donors were purchased from Centre Necker-Cabanel, Etablissement Français du Sang (EFS), Paris, France. Institut National de la Santé et de la Recherche Médicale-EFS ethical committee permission (Nu12/EFS/079) was obtained for the use of buffy coats of healthy donors. Peripheral blood mononuclear cells (PBMCs) were purified from the buffy coats by density gradient centrifugation using Ficoll-paque PREMIUM (GE healthcare, France). CD14 1 monocytes were isolated from PBMCs by using CD14 microbeads (Miltenyi Biotec). Purified monocytes were then cultured for 6 days in RPMI-1640 medium plus 10% fetal calf serum (FCS) containing cytokines GM-CSF (1000 IU/10 6 cells) and IL-4 (500 IU/10 6 cells) (both from Miltenyi Biotec) to obtain DCs 56 . The purity of DCs was .98%. DC-SIGN expression on Mo-DCs was examined by flow cytometry using fluorochrome-conjugated monoclonal antibodies (BD Biosciences) and data were analyzed by FACSDiva TM and FlowJo softwares (Tree Star, USA).
Isolation of human splenocytes. The remnant human spleen sections from individuals submitted for pathological diagnosis were obtained from service d'anatomie pathologique, Hôpital Européen Georges Pompidou, Paris, France. Only healthy spleen tissues were used for the research purpose. Since the study did not require additional sampling, an approval from an ethics committee was not required under French law according to the article L.1121-1 of the public health code. The article states that: The research organized and performed on human beings in the development of biological knowledge and medical research are permitted under the conditions laid down in this book and are hereinafter referred to by the term ''biomedical research''. The article further states that it does not imply under conditions: For research in which all actions are performed and products used in the usual way, without any additional or unusual diagnostic procedure or surveillance.
The spleen sections were collected in RPMI 1640 medium supplemented with 100 IU/ml penicillin, 100 mg/ml streptomycin, and 10% FCS. Single-cell suspension of splenocytes was obtained by mechanical disaggregation of spleen tissue pieces by using gentleMACS dissociator (Miltenyi Biotec) followed by filtration through 70-mm nylon membrane filter (BD Biosciences). Splenocytes were then subjected to FicollPaque PREMIUM density gradient centrifugation to obtain mononuclear cells. DC-SIGN expression on the splenocytes was investigated by flow cytometry using fluorochrome-conjugated monoclonal antibodies and data were analyzed by FACSDiva TM and FlowJo softwares.
Stimulation of cells. Mo-DCs (0.5 3 10 6 /ml) were cultured in RPMI 1640-10% FCS containing GM-CSF and IL-4 in a 12-well plate. The cells were then exposed to IVIg (25 mg/ml) for 48 hours to analyze the effect of IVIg on IL-33 production under noninflammatory conditions. In parallel, Mo-DCs were stimulated with either TLR4 ligand lipopolysaccharide (100 ng/ml/0.5 3 10 6 cells) (Sigma-Aldrich, France) or inflammatory cytokine cocktail (10 ng/ml each of IL-1b, IL-6 and TNF-a, all from ImmunoTools, Germany) 57 . After four hours, IVIg was added and cultures were maintained for 48 hours to analyze the effect of IVIg on IL-33 production under inflammatory conditions. Similarly, splenocytes (0.5 3 10 6 /ml) were cultured in RPMI 1640-10% FCS for 48 hours either alone or with IVIg. In addition, splenocytes were also stimulated with inflammatory cytokine cocktail and IVIg was added to the cultures after four hours. The cultures were maintained for 48 hours.
Quantification of cytokines. IL-33 in the plasma samples of the patients and in cellfree culture supernatants was quantified by ELISA (R&D systems, France). IL-4 in the plasma was also measured by ELISA (R&D systems).
Statistical analysis. Data was analyzed using Prism 5 software (GraphPad software). Two-tailed Student's t-test was used to determine the statistical significance of the data. Values of P , 0.05 were considered as statistically significant.
